Medtronic Secures FDA, CE Marks for Advanced Cardiac Mapping and Ablation Software

  • Medtronic received FDA clearance and CE Mark for Affera™ Prism-2 Mapping Software on September 30, 2026.
  • CE Mark obtained for PulseSelect ProxBox™ Adapter with Proximity Indicator software.
  • Affera Prism-2 Software enhances cardiac mapping with Beat Matching, Pace Tagging, and improved pacing stimulator.
  • PulseSelect ProxBox™ Adapter provides real-time tissue proximity feedback for safer ablation procedures.

Medtronic's regulatory wins position it to capture more of the growing cardiac ablation market, where software-driven precision is becoming a key differentiator. The enhancements align with industry trends toward reduced fluoroscopy use and more integrated electrophysiology platforms. With the PulseSelect system already in 60+ countries, the proximity feedback feature could further solidify Medtronic's leadership in pulsed field ablation technology.

Adoption Pace
How quickly hospitals and electrophysiologists will integrate the new software into existing workflows.
Competitive Response
Whether competitors like Boston Scientific or Abbott will accelerate their own software enhancements.
Revenue Impact
The extent to which these software upgrades drive procedural volume growth for Medtronic's ablation platforms.